Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Share-based Compensation (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Share-based Compensation for 9 consecutive years, with $11.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation changed N/A to $11.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $45.8 million for FY2025, 54.13% down from the prior year.
  • Share-based Compensation for Q4 2025 was $11.5 million at Soleno Therapeutics, up from $10.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $14.7 million in Q1 2025, with the low at $9.7 million in Q2 2025.